External Defibrillators Market: as AHA documentation of 356,000 or more US out-of-hospital cardiac arrest deaths annually establishes the structural emergency cardiac demand base, Stryker LIFEPAK 35 launch in June 2024 and Medtronic OmniaSecure FDA approval in April 2025 sustain the hospital and emergency medical services defibrillator capital replacement cycle, so Avive Solutions raising USD 56.50 Million in April 2024 and receiving FAA aircraft AED approval in September 2025 confirms that the public access AED market is entering a technology and distribution expansion phase that will structurally grow the addressable AED installed base above the current public venue deployment trajectory.

The global external defibrillators market size was USD 4.12 Billion in 2025 and is expected to register a revenue CAGR of 7.4% during the forecast period. Market revenue growth is driven by factors such as AHA documentation of 356,000 or more US out-of-hospital cardiac arrests annually establishing the non-discretionary emergency cardiac demand base sustaining hospital and EMS defibrillator capital procurement, the Stryker LIFEPAK 35 launch in June 2024 and Medtronic OmniaSecure FDA approval in April 2025 creating hospital and EMS defibrillator capital replacement cycles at accounts evaluating next-generation platform capabilities, and as well as the public access AED market expansion driven by Ohio AED mandate legislation in July 2024, UK GBP 1.00 Million community AED programme in 2025, China deploying 64,000 AED units in 2024, and Avive Solutions receiving FAA aircraft AED approval in September 2025 across a diverse set of regulatory and commercial expansion signals. The first driving factor is the AHA documentation of 356,000 or more US out-of-hospital cardiac arrest deaths annually, establishing the structural non-discretionary cardiac emergency demand that sustains EMS and hospital defibrillator capital procurement and pad and battery consumable revenue at healthcare systems deploying manual and semi-automated defibrillators for cardiac arrest management. The second driving factor is the hospital and EMS defibrillator capital replacement cycle generated by Stryker LIFEPAK 35 launch in June 2024 as the next-generation EMS defibrillator and Medtronic OmniaSecure FDA approval in April 2025 expanding the cardiac emergency management portfolio, combined with Medtronic CRHF FY2025 USD 6.39 Billion at 7% growth confirming the sustained cardiac device commercial momentum that generates adjacent external defibrillator replacement demand. The third driving factor is the public access AED market structural expansion across multiple simultaneous regulatory and commercial development pathways, with Ohio AED mandate legislation in July 2024 requiring AED installation at new venue categories, UK GBP 1.00 Million community AED fund in 2025, China deploying 64,000 AED units in 2024, and Avive Solutions USD 56.50 Million growth equity in April 2024 and FAA aircraft AED approval in September 2025 all confirming that the global public access AED installed base is entering an above-prior-decade growth phase. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way public access AED mandate legislation creates non-discretionary infrastructure procurement demand that expands the total AED installed base without requiring voluntary purchase decisions from venue operators, which allows each new AED mandate to add a predictable new venue category AED procurement pipeline that generates both initial capital revenue and recurring pad and battery maintenance consumable revenue at each mandated venue. Once AED mandate legislation specifies installation requirements for a new venue category such as school athletic facilities, transit stations, or aviation settings, venue operators become non-discretionary AED buyers whose procurement timeline is set by legislative compliance deadlines rather than voluntary capital allocation decisions, creating a predictable compliance procurement pipeline above the voluntary adoption market. As a result, demand and revenue share are concentrating around the AED platforms with the most established mandate compliance documentation, the most comprehensive public venue installation and maintenance service networks, and the most recognised brand positioning among compliance purchasing decision-makers at venue operator procurement teams, and the forecast tilts toward these mandate-compliance AED platforms rather than lower-profile clinical-setting AED variants competing primarily on device specification. For instance, in October 2024, Avive Solutions launched QuickRescue with RapidSOS integration, one of several commercial events that shaped the external defibrillator competitive landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the structural non-discretionary nature of cardiac emergency care equipment procurement, sustained by the AHA documentation of 356,000 or more US out-of-hospital cardiac arrest deaths annually confirming the clinical and institutional imperative for maintained defibrillator deployment at every EMS response vehicle, hospital cardiac care unit, and monitored patient care setting. Non-discretionary cardiac emergency demand works commercially because EMS systems, hospital cardiac care units, and emergency departments cannot operate without functional defibrillators certified to current performance standards, so defibrillator capital replacement on the standard 5 to 7 year EMS fleet replacement cycle and hospital maintenance contract renewal generate reliable recurring capital and service revenue that is protected from hospital cost-containment pressure by patient safety compliance requirements. The AHA 356,000 US OHCA figure establishes the public health magnitude that justifies non-discretionary public access AED deployment investment by venue operators, employers, and government programmes as a patient safety infrastructure investment rather than an optional public health expenditure. Medtronic CRHF FY2025 USD 6.39 Billion at 7% growth confirms the sustained cardiac device commercial infrastructure that generates adjacent external defibrillator capital replacement demand at hospital cardiac programmes. In June 2024, Stryker launched the LIFEPAK 35 as the next-generation hospital and advanced EMS defibrillator monitor with full-spectrum cardiac monitoring and defibrillation capability, creating a capital replacement evaluation cycle at hospital cardiac care units and advanced EMS systems managing the transition from LIFEPAK 15 and LIFEPAK 20e fleet generations. These are some of the key factors driving revenue growth of the market.

The second driver is the active technology innovation cadence across hospital, EMS, and public access AED categories creating above-depreciation-schedule capital replacement evaluation cycles at defibrillator fleet managers who would otherwise defer replacement to the end of the standard 7-year fleet depreciation cycle. Innovation-driven capital cycles work commercially because the Stryker LIFEPAK 35's clinical monitoring and defibrillation capability enhancement creates a genuine technology differentiation argument that medical directors at EMS systems and hospital cardiac care units can use to justify early replacement at accounts still managing functional but older-generation LIFEPAK 15 or LIFEPAK 20e fleets, and the Medtronic OmniaSecure FDA approval confirms sustained Medtronic cardiac device innovation that generates adjacent defibrillator platform evaluation at hospital cardiology departments. Avive Solutions raised USD 56.50 Million in growth equity in April 2024, launched QuickRescue with RapidSOS 911 integration in October 2024 enabling real-time AED location dispatch to first responders, and received FAA approval for aircraft AED deployment in September 2025 as the first AED specifically approved for commercial aviation deployment settings, confirming that the public access AED category is entering a technology and distribution expansion phase above prior-generation fixed-public-venue AED deployments. In July 2024, Ohio enacted AED mandate legislation requiring AED installation at new venue categories including school athletic facilities, creating a compliance procurement pipeline of above-voluntary-purchase AED procurement. These are some of the key factors driving revenue growth of the market.

AHA documented 356,000 or more US out-of-hospital cardiac arrest deaths annually, with survival rates as low as 10% for unwitnessed OHCA without bystander AED use and as high as 70% for witnessed cardiac arrest with immediate AED deployment. The OHCA survival rate differential confirms that AED deployment density is a direct mortality determinant, not a marginal clinical benefit, which is the institutional justification that drives public health mandates and venue operator compliance procurement above the voluntary purchase market for public access AEDs.

The third driver is the concurrent public access AED installed base expansion across multiple geographies through both legislative mandate and commercial programme investment, with the Ohio AED mandate, UK community AED fund, China national AED deployment programme, and Avive FAA aircraft approval all materialising within the same 18-month window and collectively confirming that public access AED deployment is becoming a multi-geography government and commercial infrastructure priority rather than a US-centric voluntary safety investment. Public access AED mandate expansion works commercially because legislative mandate converts reluctant venue operators from voluntary to non-discretionary AED purchasers, and each new venue category covered by mandate legislation adds a predictable compliance procurement pipeline that generates both initial capital and recurring maintenance consumable revenue without requiring voluntary purchase decision conversion at each individual venue account. Ohio enacted AED mandate legislation in July 2024 requiring AED installation at school athletic facilities, large employer workplaces, and public gathering venues above specified capacity thresholds. UK allocated GBP 1.00 Million to community AED programme expansion in 2025, targeting community defibrillator installation at village halls, sports clubs, and rural public locations. China deployed 64,000 AED units across public venues in 2024, representing the largest single-year public access AED deployment programme outside the United States. Avive Solutions received FAA approval for commercial aviation AED deployment in September 2025, opening the global commercial aviation fleet of approximately 25,000 active aircraft as a new public access AED procurement channel. These are some of the key factors driving revenue growth of the market.

However, the external defibrillators market faces adoption constraints from Philips HeartStart portfolio exit disrupting the installed base and cost barriers limiting public access AED deployment in lower-income communities. Because Philips announced its exit from emergency care hardware including HeartStart AED systems in January 2025, the millions of Philips HeartStart AEDs deployed at US and global public access venues will require replacement as the HeartStart maintenance ecosystem including pad supply, software updates, and technical service contracts is progressively discontinued, creating transitional confusion for venue operators evaluating replacement platforms and a transitional gap period during which non-functional or expired Philips HeartStart units at public venues reduce effective public access AED coverage without a clear compliance guidance pathway to replacement. Cost barriers are a second constraint, as AED capital costs of USD 1,200 to USD 3,000 per unit and annual pad and battery maintenance costs of USD 100 to USD 300 per unit create procurement barriers for compliance purchasing at lower-income public venue categories targeted by AED mandate legislation including community centres, food banks, lower-income school districts, and rural volunteer fire stations, constraining mandate compliance velocity at the most resource-constrained venue categories absent subsidy or grant funding mechanisms. International AED regulatory variation is the third constraint, as IEC 60601-2-4 certification requirements, defibrillation energy protocol variation between US and European guidelines, and national lay responder training programme specifications create product and documentation complexity for globally marketed AED platforms that adds compliance cost and extends market entry timelines in markets where public access AED deployment is at earlier stages than North America. These factors substantially limit external defibrillators market growth over the forecast period.

Based on product, the global external defibrillators market is segmented into automated external defibrillators, manual external defibrillators, semi-automated external defibrillators, and wearable cardioverter defibrillators. Automated external defibrillators hold the largest revenue share at approximately 48% of 2025 market revenue, driven by public access AED market expansion through Ohio mandate July 2024, China 64,000 units 2024, UK GBP 1.00 Million community programme 2025, and Avive FAA aircraft approval September 2025 across multiple simultaneous public access AED deployment pathways. Wearable cardioverter defibrillators are expected to register the most rapid revenue growth rate in the global external defibrillators market over the forecast period, driven by ZOLL LifeVest continued adoption and Philips HeartStart WCD transition patients migrating to alternative WCD platforms as Philips service support is discontinued.

Based on regional analysis, the external defibrillators market in North America accounted for largest revenue share in 2025 at approximately 38% of global revenue. The United States drives the regional position through the highest public access AED deployment density globally, the largest EMS fleet defibrillator capital procurement market, and the highest hospital cardiac arrest code team defibrillator capital investment. AHA 356,000 or more US OHCA annual deaths establishes the structural demand base. Ohio AED mandate July 2024 creates a new compliance procurement pipeline above the established voluntary US public access AED market. External defibrillator supply chains are not materially affected by Iran-US sanctions, as defibrillator electronic component manufacturing is primarily concentrated in US, Japan, and European facilities outside the Strait of Hormuz logistics corridors.

The market in Asia Pacific is expected to register the fastest revenue growth rate over the forecast period at approximately 28% of global revenue in 2025. Japan, China, and South Korea represent the three largest national external defibrillator markets in Asia Pacific. China's deployment of 64,000 AED units in 2024 represents the largest single-year public access AED deployment programme outside the United States, driven by national government public access AED infrastructure investment targeting railway stations, airports, sports venues, and commercial centres in major Chinese cities. Japan has the highest public access AED deployment density in Asia outside Australia, with Nihon Kohden and ZOLL Medical Japan primary AED vendors at Japanese public venue accounts.

The market in Europe is expected to register a steady revenue growth rate over the forecast period at approximately 26% of global revenue. Germany, France, the United Kingdom, and Italy represent the four largest national external defibrillator markets in Europe. The UK GBP 1.00 Million community AED programme in 2025 demonstrates continued government investment in public access AED infrastructure above the established UK public defibrillator registration network. Schiller AG Americas and CU Medical System are the primary European public access AED vendors alongside ZOLL Medical and Cardiac Science at European venue accounts.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national external defibrillator markets. Brazil's private hospital network is the primary external defibrillator capital procurement setting, and public access AED deployment in Latin American urban centres is at an earlier stage than North America or Europe, creating a significant addressable growth opportunity as AED cost economics improve and regional public health programme investment in cardiac emergency infrastructure expands.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and UAE represent the primary commercial markets. Saudi Vision 2030 healthcare infrastructure investment includes AED deployment at sports facilities, airports, and major commercial venues as part of national emergency medical services capability expansion, creating new public access AED procurement channels at GCC government-funded infrastructure projects.